Skip to main content

Cardiol Therapeutics Inc.

corporate_fare Company Profile

Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Exchange: NASDAQSector: Life Sciences

Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a publicly traded company in the Life Sciences sector. Wiseek monitors CRDL SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Cardiol Therapeutics Reports Q1 2026 Results, $27.7M Cash, and Extends Runway into Q4 2027
  • Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in Journal of American Heart Association
  • Cardiol Therapeutics Expands Phase III MAVERIC Trial Network, Reaches 75% Patient Enrollment
  • Cardiol Therapeutics Secures Over $30M in Recent Financings, Advances Clinical Pipeline, and Appoints Key Board Member
  • Cardiol Therapeutics Publishes Positive Phase II ARCHER Study Results in ESC Heart Failure

show_chartPrice Chart

Loading chart...

feed CRDL - Latest Insights

CRDL
May 11, 2026, 5:27 PM EDT
Filing Type: 6-K
Importance Score:
7
Cardiol Therapeutics Reports Q1 2026 Results, $27.7M Cash, and Extends Runway into Q4 2027
Sentiment: Positive
View Wiseek Article
CRDL
May 07, 2026, 7:37 AM EDT
Filing Type: 6-K
Importance Score:
8
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in Journal of American Heart Association
Sentiment: Positive
View Wiseek Article
CRDL
Apr 28, 2026, 7:50 AM EDT
Filing Type: 6-K
Importance Score:
8
Cardiol Therapeutics Expands Phase III MAVERIC Trial Network, Reaches 75% Patient Enrollment
Sentiment: Positive
View Wiseek Article
CRDL
Mar 31, 2026, 4:47 PM EDT
Filing Type: 40-F
Importance Score:
8
Cardiol Therapeutics Secures Over $30M in Recent Financings, Advances Clinical Pipeline, and Appoints Key Board Member
Sentiment: Positive
View Wiseek Article
CRDL
Feb 10, 2026, 7:32 AM EST
Filing Type: 6-K
Importance Score:
8
Cardiol Therapeutics Publishes Positive Phase II ARCHER Study Results in ESC Heart Failure
Sentiment: Positive
View Wiseek Article
CRDL
Feb 02, 2026, 4:01 PM EST
Filing Type: 6-K
Importance Score:
7
Cardiol Therapeutics Files Definitive Agreements for $14.85M Bought Deal Financing
Sentiment: Neutral
View Wiseek Article
CRDL
Jan 23, 2026, 9:26 AM EST
Filing Type: 6-K
Importance Score:
8
Cardiol Therapeutics Closes $14.85M Bought Deal Financing at Premium, Including Full Over-Allotment
Sentiment: Neutral
View Wiseek Article
CRDL
Jan 16, 2026, 8:57 AM EST
Filing Type: 6-K
Importance Score:
8
Cardiol Therapeutics Secures $13.5M Financing at Premium to Market Price
Sentiment: Neutral
View Wiseek Article
CRDL
Jan 13, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8
Cardiol Therapeutics Achieves 50% Patient Enrollment in Pivotal Phase III MAVERIC Trial
Sentiment: Positive
View Wiseek Article